XORTX Therapeutics Inc. announce the appointment of Dr. David MacDonald as Chief Technology Officer (CTO). Dr. MacDonald has an over 30-year record of achievement in drug development and leadership in pharma and biotech, achieving critical, value-inflection milestones for those companies. Prior to XORTX, Dr. MacDonald held positions as CTO and later President of MSI Methylation Sciences Inc.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.94 CAD | +10.36% | +17.61% | +35.86% |
05-17 | XORTX Therapeutics Reprices Warrants Connected With U.S. IPO | MT |
05-17 | XORTX Therapeutics Brief: Says Repriced Balance of Warrants Issued in Connection with October 2021 US IPO | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+35.86% | 7.57M | |
+11.31% | 115B | |
+12.71% | 106B | |
-4.24% | 24.69B | |
-2.33% | 21.97B | |
-6.03% | 19.27B | |
-12.84% | 17.56B | |
-40.50% | 17.32B | |
+6.75% | 14.03B | |
+32.24% | 12.13B |
- Stock Market
- Equities
- XRTX Stock
- News XORTX Therapeutics Inc.
- XORTX Therapeutics Inc. Appoints Dr. David Macdonald as Chief Technology Officer